In multivariable analysis, six clinicopathologic variables were significantly associated with time to recurrence: ulceration, tumor thickness, tumor location, neurotropism (tumor growth along nerves), ...
Circulating tumor DNA levels a few weeks after immunotherapy initiation could help identify patients with melanoma at greatest risk for recurrence or death.A retrospective analysis showed individuals ...
Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...
A key takeaway from the analysis was that baseline ctDNA levels alone were not significantly predictive or prognostic. The ...
Study results were recently shared at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in Phoenix. NCCN Cutaneous ...
Among all patients studied, 2.6% nodal positivity and 97.8% three-year recurrence-free survival (RFS) was observed in those predicted to have ...
“When we talk about recurrence of melanoma, we actually worry more about what we cannot see, what's on the inside,” Dr. Justine V. Cohen of the Dana-Farber Cancer Institute told CURE®. Patients with ...
Lytix Biopharma AS ( (DE:6BG)) has issued an announcement. Lytix Biopharma will present final Phase II results from its ATLAS-IT-05 study of ruxotemitide (LTX-315) in combination with pembrolizumab at ...
About a month after Pfizer CEO Albert Bourla, Ph.D., told investors that the Big Pharma’s pipeline pruning was mostly done, ...
In an interview, Vincent Ma, MD, discussed how ctDNA levels after the first cycle of immune checkpoint inhibitor in melanoma ...
The Initiative helps clinicians align their clinical practice with updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Melanoma (Version 1.2026) frameworkProvides T1b and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results